Chemicals - Specialty
Compare Stocks
2 / 10Stock Comparison
KWR vs CBT
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
KWR vs CBT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Chemicals - Specialty | Chemicals - Specialty |
| Market Cap | $2.46B | $4.30B |
| Revenue (TTM) | $1.93B | $3.58B |
| Net Income (TTM) | $4M | $285M |
| Gross Margin | 34.4% | 24.8% |
| Operating Margin | 3.7% | 15.7% |
| Forward P/E | 19.2x | 13.2x |
| Total Debt | $929M | $1.22B |
| Cash & Equiv. | $180M | $258M |
KWR vs CBT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Quaker Chemical Cor… (KWR) | 100 | 83.0 | -17.0% |
| Cabot Corporation (CBT) | 100 | 230.7 | +130.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KWR vs CBT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
KWR is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 2.7%, EPS growth -102.2%, 3Y rev CAGR -1.0%
- Lower volatility, beta 1.35, Low D/E 67.5%, current ratio 2.42x
- 2.7% revenue growth vs CBT's -7.0%
CBT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 4 yrs, beta 0.78, yield 2.1%
- 115.6% 10Y total return vs KWR's 81.8%
- Beta 0.78, yield 2.1%, current ratio 1.61x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 2.7% revenue growth vs CBT's -7.0% | |
| Value | Lower P/E (13.2x vs 19.2x) | |
| Quality / Margins | 8.0% margin vs KWR's 0.2% | |
| Stability / Safety | Beta 0.78 vs KWR's 1.35 | |
| Dividends | 1.4% yield, 6-year raise streak, vs CBT's 2.1% | |
| Momentum (1Y) | +44.4% vs CBT's +16.2% | |
| Efficiency (ROA) | 7.4% ROA vs KWR's 0.2%, ROIC 17.4% vs 6.6% |
KWR vs CBT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
KWR vs CBT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — KWR and CBT each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CBT is the larger business by revenue, generating $3.6B annually — 1.9x KWR's $1.9B. CBT is the more profitable business, keeping 8.0% of every revenue dollar as net income compared to KWR's 0.2%. On growth, KWR holds the edge at +8.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.9B | $3.6B |
| EBITDAEarnings before interest/tax | $143M | $731M |
| Net IncomeAfter-tax profit | $4M | $285M |
| Free Cash FlowCash after capex | $143M | $459M |
| Gross MarginGross profit ÷ Revenue | +34.4% | +24.8% |
| Operating MarginEBIT ÷ Revenue | +3.7% | +15.7% |
| Net MarginNet income ÷ Revenue | +0.2% | +8.0% |
| FCF MarginFCF ÷ Revenue | +7.4% | +12.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.5% | -3.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +54.8% | -23.1% |
Valuation Metrics
CBT leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, CBT's 6.8x EV/EBITDA is more attractive than KWR's 11.9x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $2.5B | $4.3B |
| Enterprise ValueMkt cap + debt − cash | $3.2B | $5.3B |
| Trailing P/EPrice ÷ TTM EPS | -1013.29x | 13.69x |
| Forward P/EPrice ÷ next-FY EPS est. | 19.17x | 13.23x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 11.86x | 6.79x |
| Price / SalesMarket cap ÷ Revenue | 1.30x | 1.16x |
| Price / BookPrice ÷ Book value/share | 1.80x | 2.62x |
| Price / FCFMarket cap ÷ FCF | 30.51x | 11.01x |
Profitability & Efficiency
CBT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
CBT delivers a 16.8% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $0 for KWR. KWR carries lower financial leverage with a 0.67x debt-to-equity ratio, signaling a more conservative balance sheet compared to CBT's 0.71x. On the Piotroski fundamental quality scale (0–9), CBT scores 6/9 vs KWR's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +0.3% | +16.8% |
| ROA (TTM)Return on assets | +0.2% | +7.4% |
| ROICReturn on invested capital | +6.6% | +17.4% |
| ROCEReturn on capital employed | +7.6% | +21.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.67x | 0.71x |
| Net DebtTotal debt minus cash | $749M | $957M |
| Cash & Equiv.Liquid assets | $180M | $258M |
| Total DebtShort + long-term debt | $929M | $1.2B |
| Interest CoverageEBIT ÷ Interest expense | 1.41x | 14.72x |
Total Returns (Dividends Reinvested)
CBT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CBT five years ago would be worth $14,375 today (with dividends reinvested), compared to $6,377 for KWR. Over the past 12 months, KWR leads with a +44.4% total return vs CBT's +16.2%. The 3-year compound annual growth rate (CAGR) favors CBT at 7.5% vs KWR's -11.5% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +2.8% | +23.6% |
| 1-Year ReturnPast 12 months | +44.4% | +16.2% |
| 3-Year ReturnCumulative with dividends | -30.6% | +24.1% |
| 5-Year ReturnCumulative with dividends | -36.2% | +43.8% |
| 10-Year ReturnCumulative with dividends | +81.8% | +115.6% |
| CAGR (3Y)Annualised 3-year return | -11.5% | +7.5% |
Risk & Volatility
CBT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CBT is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than KWR's 1.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CBT currently trades 97.4% from its 52-week high vs KWR's 77.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.35x | 0.78x |
| 52-Week HighHighest price in past year | $183.00 | $84.60 |
| 52-Week LowLowest price in past year | $99.18 | $58.33 |
| % of 52W HighCurrent price vs 52-week peak | +77.5% | +97.4% |
| RSI (14)Momentum oscillator 0–100 | 56.3 | 63.9 |
| Avg Volume (50D)Average daily shares traded | 178K | 371K |
Analyst Outlook
Evenly matched — KWR and CBT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Wall Street rates KWR as "Buy" and CBT as "Buy". Consensus price targets imply 24.3% upside for KWR (target: $176) vs -5.4% for CBT (target: $78). For income investors, CBT offers the higher dividend yield at 2.15% vs KWR's 1.39%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $176.33 | $78.00 |
| # AnalystsCovering analysts | 14 | 15 |
| Dividend YieldAnnual dividend ÷ price | +1.4% | +2.1% |
| Dividend StreakConsecutive years of raises | 6 | 4 |
| Dividend / ShareAnnual DPS | $1.97 | $1.77 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.7% | +3.9% |
CBT leads in 4 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 2 categories are tied.
KWR vs CBT: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is KWR or CBT a better buy right now?
For growth investors, Quaker Chemical Corporation (KWR) is the stronger pick with 2.
7% revenue growth year-over-year, versus -7. 0% for Cabot Corporation (CBT). Cabot Corporation (CBT) offers the better valuation at 13. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Quaker Chemical Corporation (KWR) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — KWR or CBT?
On forward P/E, Cabot Corporation is actually cheaper at 13.
2x.
03Which is the better long-term investment — KWR or CBT?
Over the past 5 years, Cabot Corporation (CBT) delivered a total return of +43.
8%, compared to -36. 2% for Quaker Chemical Corporation (KWR). Over 10 years, the gap is even starker: CBT returned +115. 6% versus KWR's +81. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — KWR or CBT?
By beta (market sensitivity over 5 years), Cabot Corporation (CBT) is the lower-risk stock at 0.
78β versus Quaker Chemical Corporation's 1. 35β — meaning KWR is approximately 72% more volatile than CBT relative to the S&P 500. On balance sheet safety, Quaker Chemical Corporation (KWR) carries a lower debt/equity ratio of 67% versus 71% for Cabot Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — KWR or CBT?
By revenue growth (latest reported year), Quaker Chemical Corporation (KWR) is pulling ahead at 2.
7% versus -7. 0% for Cabot Corporation (CBT). On earnings-per-share growth, the picture is similar: Cabot Corporation grew EPS -10. 4% year-over-year, compared to -102. 2% for Quaker Chemical Corporation. Over a 3-year CAGR, KWR leads at -1. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — KWR or CBT?
Cabot Corporation (CBT) is the more profitable company, earning 8.
9% net margin versus -0. 1% for Quaker Chemical Corporation — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CBT leads at 16. 7% versus 9. 4% for KWR. At the gross margin level — before operating expenses — KWR leads at 36. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is KWR or CBT more undervalued right now?
On forward earnings alone, Cabot Corporation (CBT) trades at 13.
2x forward P/E versus 19. 2x for Quaker Chemical Corporation — 5. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KWR: 24. 3% to $176. 33.
08Which pays a better dividend — KWR or CBT?
All stocks in this comparison pay dividends.
Cabot Corporation (CBT) offers the highest yield at 2. 1%, versus 1. 4% for Quaker Chemical Corporation (KWR).
09Is KWR or CBT better for a retirement portfolio?
For long-horizon retirement investors, Cabot Corporation (CBT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
78), 2. 1% yield, +115. 6% 10Y return). Both have compounded well over 10 years (CBT: +115. 6%, KWR: +81. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between KWR and CBT?
Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KWR is a small-cap quality compounder stock; CBT is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.